The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of HWK-007, a next-generation, protein tyrosine kinase 7 (PTK7)–targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors.
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Pfizer; Regeneron; Vertex
Consulting or Advisory Role - AADi; Enlaza Therapeutics; Pliant; Whitehawk Therapeutics
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Arcus Biosciences (Inst); Artios (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Boundless Bio Therapeutics (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Circle Pharma (Inst); Compugen (Inst); Context Therapeutics (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Day One Biopharmaceuticals (Inst); Debiopharm Group (Inst); Deciphera (Inst); EvolveImmune Therapeutics (Inst); Exelixis (Inst); Exscientia (Inst); FoRx Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Tesaro (Inst); Halda Therapeutics (Inst); Helsinn Therapeutics (Inst); Iambic Therapeutics (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Ipsen (Inst); Johnson & Johnson/Janssen (Inst); Johnson & Johnson/Janssen (Inst); KLUS Pharma (Inst); Kumquat Biosciences (Inst); Macrogenics (Inst); Mbrace Therapeutics (Inst); MediLink Therapeutics (Inst); Menarini Group (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mitsubishi Tanabe Pharma (Inst); Moderna Therapeutics (Inst); Monte Rosa Therapeutics (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Olema Pharmaceuticals (Inst); Opna Bio (Inst); Pfizer (Inst); Pliant (Inst); Quanta Therapeutics (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Seagen (Inst); Takeda (Inst); Third Arc Bio (Inst); Treeline Biosciences (Inst); VelaVigo Bio (Inst); Vividion Therapeutics (Inst); Zymeworks (Inst)
 
Jennifer Segar
No Relationships to Disclose
 
Sheena Sahota
Stock and Other Ownership Interests - Revolution Medicines (I)
 
Edward Spindler
Employment - Whitehawk Therapeutics
Stock and Other Ownership Interests - AADi; Whitehawk Theraapeutics
Patents, Royalties, Other Intellectual Property - The Medicines Company
 
Aamena Chaudhry
Employment - Promontory Therapeutics; Whitehawk Therapeutics
Stock and Other Ownership Interests - Promontory Therapeutics; Whitehawk Therapeutics
 
Ashwini Pai
Employment - Whitehawk Therapeutics
Stock and Other Ownership Interests - Whitehawk Therapeutics
 
Margaret Dugan
Employment - BeiGene; Dracen; Schrodinger; Whitehawk Therapeutics
Leadership - BeiGene; Schrodinger; Whitehawk
Stock and Other Ownership Interests - Alcon; BeiGene; Merck; Merck; Novartis; Schrodinger; Whitehawk
Consulting or Advisory Role - BeiGene; Dracen; Schrodinger
Travel, Accommodations, Expenses - BeiGene
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Lilly; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); crispr therapeutics; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Revolution Medicines; Sanofi; Sanofi; Synthekine; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; lepu biopharma (Inst); Lilly (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Tango Therapeutics (Inst)